📊 Incidence & Definitions
Increases with decreasing gestational age: 10-15% at 28 weeks, >50% at <26 weeks. NIH definition: oxygen requirement at 36 weeks PMA; severity graded mild, moderate, severe.
🧬 Pathophysiology
Arrested alveolar development (simplified alveoli), dysmorphic capillaries, inflammation (cytokines, neutrophils), oxidative stress, mechanical ventilation injury (volutrauma, oxygen toxicity). Chorioamnionitis and genetic susceptibility.
🩺 Clinical features (respiratory)
Tachypnoea, subcostal/intercostal retractions, wheeze, crackles, hypoxaemia (oxygen dependency), hypercapnia, pulmonary hypertension (PHT). Exacerbations triggered by viral infections (RSV).
❤️ Extrapulmonary complications
Growth failure (poor weight gain), neurodevelopmental delay (higher risk cerebral palsy, cognitive deficits), GERD (gastroesophageal reflux), anaemia of prematurity, osteopenia/metabolic bone disease, systemic hypertension.
💊 Management (multidisciplinary)
Respiratory: CPAP, nasal high-flow, low-flow oxygen (target SpO2 90-95%), diuretics (spironolactone, thiazides, furosemide), bronchodilators (salbutamol), inhaled corticosteroids (budesonide – limited evidence). Nutrition: high-calorie formula/ breastmilk fortifier, vitamin D, iron, calcium. RSV prophylaxis (palivizumab monthly during season). Treat pulmonary hypertension (sildenafil, bosentan). Avoid routine systemic steroids.
📈 Prognosis & Future
Mortality has decreased (improved perinatal care). Long-term: asthma-like symptoms, reduced exercise capacity, recurrent wheeze, increased risk of COPD in adulthood. Pulmonary hypertension may persist. Future strategies: stem cell therapy (mesenchymal stromal cells), antioxidants (vitamin A, N-acetylcysteine), cytokine modulation (azithromycin), less invasive ventilation (HFOV, volume-targeted), targeted postnatal steroids.